Immunomodulation and sepsis - Impact of the microorganisms;Immunomodulation et sepsis - Impact de l'agent pathogène

Reanimation

Volumn 12, Issue 3, 2003, Pages 182-191

  Moine, P ^a   Asehnoune, K ^b   Edouard, A ^b   Payen, D ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

^b BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR REL; VIRULENCE FACTOR;

BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; EVOLUTION; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION; INFLAMMATION; NONHUMAN; PATHOGENESIS; PHENOTYPE; REVIEW; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0037785261     PISSN: 16240693     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1624-0693(03)00041-0     Document Type: Review

References (59)

1. American college of chest physicians/Society of critical care medicine consensus conference. Definitions for sepsis and multiple organ failure, and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
2. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997;112:235-43.
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
4. Hornef MW, Wick MJ, Rhen M, Normack S. Bacterial strategies for overcoming host innate and adaptative immune responses. Nature Immunol 2002;3:1033-40.
5. Alonso de Velasco E, Verheul AFM, Snippe H. S. pneumoniae: virulence factors, pathogenesis, and vaccines. Microbiol Rev 1995;59:591-603.
6. Cundell D, Masure HR, Tuomanen EI. The molecular basis of pneumococcal infection: a hypothesis. Clin Inf Dis 1995;21:S204-12.
7. Van Delden C, Iglewski BH. Cell-to-cell signaling and P. aeruginosa infections. Emerging Infectious Diseases 1998;4:551-60.
8. Rumbaugh KP, Griswold JA, Hamood AN. The role of quorum sensing in the in vivo virulence of P. aeruginosa. Microbes and Infection 2000;2:1721-31.
9. Polissi A, Pontiggia A, Feger G, Altieri M, Mottl H, Ferrari L, et al. Large-scale identification of virulence genes from S. pneumoniae. Infect Immun 1998;66:5620-9.
10. Hava DL, Camilli A. Large-scale identification of serotype 4 S. pneumoniae virulence Factors. Molecular Microbiology 2002;45:1389-406.
11. Berry AM, Paton JC. Additive attenuation of virulence of S. pneumoniae by mutation of the genes encoding pneumolysin and other putative pneumococcal virulence proteins. Infect Immun 2000;68:133-40.
12. Weiser JN, Austrian R, Sreenivasan PK. Masure H.R., Phase variation in pneumococcal opacity: Relationship between colonial morphology and nasopharyngeal colonization. Infect Immun 1994;62:2582-9.
13. Cundell D, Masure HR, Tuomanem EI. The molecular basis of pneumococcal infection: a hypothesis. Clin Infect Dis 1995;21(suppl. 3):S204-12.
14. Cundell DR, Tuomanem EI. Receptor specificity of adherence of S. pneumoniae to human type-II pneumocyte and vascular endothelial cells in vitro. Microb Pathog 1994;17:361-74.
15. Kim JO, Weiser JN. Association of intrastrain phase variation in quantity of capsular polysaccharide and teichoic acid with virulence of S. pneumoniae. J Infect Dis 1998;177:368-77.
16. Overweg K, Pericone CD, Verhoef GG, Weiser JN, Meiring HD, De Jong AP, et al. Differential protein expression in phenotypic variants of S. pneumoniae. Infect Immun 2000;68:4604-10.
17. Ogunniyi AD, Giammarinaro P, Paton JC. The genes encoding virulence-associated proteins and the capsule of S. pneumoniae are upregulated and differentially expressed in vivo. Microbiology 2002;148:2405-53.
18. De Kievit TR, Iglewski BH. Bacterial quorum sensing in pathogenic relationships. Infect Immun 2000;68:4839-49.
19. Houldsworth S, Andrew PW, Mitchell TJ. Pneumolysin stimulates production of tumor necrosis factor alpha and interleukin-1 beta by human mononuclear phagocytes. Infect Immun 1994;62:1501-3.
20. Mileski W, Harlan J, Rice C, Winn R. S. pneumoniae-stimulated macrophages induce neutrophils to emigrate by a CD-18-independent mechanism of adherence. Circ Shock 1990;31:259-67.
21. Heumann D, Barras C, Severin A, Glauser MP, Tomasz A. Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes. Infect Immun 1994;62:2715-21.
22. Simpson SQ, Singh R, Bice DE. Heat-killed pneumococci and pneumococcal capsular polysaccharides stimulate tumor necrosis factor-alpha production by murine macrophages. Am J Respir Cell Mol Biol 1994;10:284-9.
23. Riesenfeld-Orn I, Wolpe S, Garcia-Bustos JF, Hoffmann MK, Tuomanen E. Production of interleukin-1 but not tumor necrosis factor by human monocytes stimulated with pneumococcal cell surface components. Infect Immun 1989;57:1890-3.
24. Cockeran R, Durandt C, Feldman C, Mitchell TJ, Anderson R. Pneumolysin activates the synthesis and release of interleukin-8 by human neutrophils in vitro. J Infect Dis 2002;186:562-5.
25. Rubins JB, Pomeroy CL. Role of gamma interferon in the pathogenesis of bacteremic pneumococcal pneumonia. Infect Immun 1997;65:2975-7.
26. DiMango E, Zar HJ, Bryan R, Prince A. Diverse P. aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8. J Clin Investig 1995;96:2204-10.
27. Epelman S, Neely GG, Ma LL, Gjomarkal M, Pace E, Melis M, et al. Distinct fates of monocytes and T cells directly activated by P. aeruginosa exoenzyme S. J Leukoc Biol 2002;71:458-68.
28. Denning GM, Wollenweber LA, Railsback MA, Cox CD, Stoll LL, Britigan BE. Pseudomonas pyocyanin increases interleukin-8 expression by human airway epithelial cells. Infect Immun 1998;66:5777-84.
29. Mori N, Oishi K, Sar B, Mukaida N, Nagatake T, Matsushima K, et al. Essential role of transcription factor nuclear factorkappaB in regulation of interleukin-8 gene expression by nitrite reductase from P. aeruginosa in respiratory epithelial cells. Infect Immun 1999;67:3872-8.
30. Cusumano V, Tufano MA, Mancuso G, Carbone M, Rossano F, Fera MT, et al. Porins of P. aeruginosa induce release of tumor necrosis factor alpha and interleukin-6 by human leukocytes. Infect Immun 1997;65:1683-7.
31. Schultz MJ, Speelman P, Zaat SAJ, Hack CE, van Deventer SJH, Van Der Poll T. The effect of Pseudomonas exotoxin A on cytokine production in whole blood exposed to P. aeruginosa. FEMS Immunology and Medical Microbiology 2000;29:227-32.
32. Telford G, Wheeler D, Williams P, Tomkins PT, Appleby P, Sewell H, et al. The P. aeruginosa quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone has immunomodulatory activity. Infect Immun 1998;66:36-42.
33. Boldrick JC, Alizadeh AA, Diehn M, Dudoit S, Liu CL, Belcher CE, et al. Stereotyped and specific gene expression programs in human innate immune response to bacteria. PNAS 2002;99:972-7.
34. Hessle C, Andersson B, Wold AE. Gram-positive bacteria are potent inducers of monocytic interleukin-12 (IL-12) while gram-negative bacteria preferentially stimulate IL-10 production. Infect Immun 2000;68:3581-6.
35. Jiang Y, Magli L, Russo M. Bacterium-dependent induction of cytokines in mononuclear cells and their pathologic consequences in vivo. Infect Immun 1999;67:2125-30.
36. Silverstein R, Norimatsu M, Morrison DC. Fundamental differences during gram-positive versus gram-negative sepsis become apparent during bacterial challenge of D-galactosamide-treated mice. J Endotoxin Res 1997;4:173-81.
37. Kragsbjerg P, Soderquist B, Holmberg H, Vikerfors T, Danielsson D. Production of tumor necrosis factor-alpha and interleukin-6 in whole blood stimulated by live Gram-negative and Gram-positive bacteria. Clin Microbiol Infect 1998;4:129-34.
38. Ingalls RR, Rice PA, Qureshi N, Takayama K, Lin JS, Golenbock DT. The inflammatory cytokine resposne to Chlamydia trachomatis infection is endotoxin mediated. Infect Immun 1995;63:3125-30.
39. Jotwani R, Tanaka Y, Watanabe K, Tanaka-Bandoh K, Kato N, Ueno K. Comparison of cytokine induction by lipopolysaccharide of Bacteroides fragilis with Salmonella typhimurium in mice. Microbiol Immunol 1994;38:763-6.
40. Cavaillon JM, Cavaillon NH. Characterization of the induction of human interleukin-1 by endotoxins. In: Brequet P, editor. Lipid Mediators in the Immunology of Burn and Sepsis. London: Plenum Press; 1987.
41. Zughaier SM, Ryley HC, Jackson SK. Lipopolysaccharides (LPS) from Burkholderia cepacia is more active than LPS from Pseudomonoas aeruginosa and Stenotrophomonas maltophilia in stimulating tumor necrosis factor alpha from human monocytes. Infect Immun 1999;67:1505-7.
42. Koyama S, Sato E, Nomura H, Kubo K, Miura M, Yamashita T, et al. The potential of various lipopolysaccharides to release IL-8 and G-CSF. Am J Physiol Lung Cell Mol Physiol 2000;278:L658-66.
43. Pulendran B, Kumar P, Cutler C, Mohamadzadeh M, Van Dyke T, Banchereau J. Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J Immunol 2001;167:5067-76.
44. Mohler J., Azoulay-Dupuis E., Amory-Rivier E., Mazoit J.X., Bédos J.P., Rieux V. et al., S. pneumoniae strain-dependent lung inflammatory responses in a murine model of pneumococcal pneumonia, Intensive Care Med, in Press.
45. Huang Q, Liu D, Majewski P, Schulte LC, Korn JM, Young RA, et al. The plasticity of dendritic cell responses to pathogens and their components. Science 2001;294:870-5.
46. Arcaroli J, Kupfner J, Yum OK, Shenkar R, Park JS, Abraham E. Lipopolysaccharide-induced neutrophil gene expression under in vivo or in vitro conditions. Chest 2002;121:76S.
47. Senftleben U, Karin M. The IKK/NF-kappa B pathway. Crit Care Med 2002;30:S18-26.
48. Tak PP, Firestein GS. NF-κB: a key role in inflammatory diseases. J Clin Invest 2001;107:7-11.
49. Ulevitch RJ. New therapeutic targets revealed through investigations of innate immunity. Crit Care Med 2001;29:S8-S12.
50. Zhang G, Ghosh S. Toll-like receptor-mediated NF-κB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest 2001;107:13-9.
51. Abraham E. NF-κB activation. Crit Care Med 2000;28:N100-4.
52. May MJ, Ghosh S. Signal transduction through NF-κB. Immunol Today 1998;19:80-8.
53. Kopp EB, Medzhitov R. The Toll-receptor family and control of innate immunity. Curr Opin Immunol 1999;11:13-8.
54. Kitamura M. NF-κB-mediated self defence of macrophages faced with bacteria. Eur J Immunol 1999;29:1647-55.
55. Tato CM, Hunter CA. Host-pathogen interactions: Subversion and utilization of NF-κB pathway durinf infection. Infect Immun 2002;70:3311-7.
56. Grassmé H, Kirschnek S, Riethmueller J, Riehle A, Von Kürthy G, Lang F, et al. CD95/CD95 ligand interactions on epithelial cells in host defence to P. aeruginosa. Science 2000;290:527-30.
57. Wahl C, Oswald F, Simnacher U, Weiss S, Marre R, Essig A. Survival of Chlamydia pneumoniae-infected mono mac 6 cells is dependent on NF-κB binding activity. Infect Immun 2001;69:7039-45.
58. Gray ML, Killinger AH. Listeria monocytogenes and listeric infections. Bacteriol Rev 1996;30:309-82.
59. Cahir-McFarland ED, Davidson DM, Schauer SL, Duong J, Kieff E. NF-κB inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci USA 2000;97:6055-60.